Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for QIAGEN N.V. (QGEN : NYSE)
 
 • Company Description   
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.

Number of Employees: 6,000

 
 • Price / Volume Information   
Yesterday's Closing Price: $45.27 Daily Weekly Monthly
20 Day Moving Average: 889,746 shares
Shares Outstanding: 227.07 (millions)
Market Capitalization: $10,279.62 (millions)
Beta: 0.33
52 Week High: $58.00
52 Week Low: $41.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.27% 9.79%
12 Week -9.64% 1.55%
Year To Date -18.55% -0.49%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
HULSTERWEG 82
-
PL VENLO,P7 5912
NLD
ph: 31-77-355-6600
fax: 31-77-355-6658
ir@qiagen.com http://www.qiagen.com
 
 • General Corporate Information   
Officers
Thierry Bernard - Chief Executive Officer
Roland Sackers - Chief Financial Officer
Lawrence A. Rosen - Director
Elaine Mardis - Director
Ross L. Levine - Director

Peer Information
QIAGEN N.V. (CORR.)
QIAGEN N.V. (RSPI)
QIAGEN N.V. (CGXP)
QIAGEN N.V. (BGEN)
QIAGEN N.V. (GTBP)
QIAGEN N.V. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N72482123
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 227.07
Most Recent Split Date: 1.00 (0.96:1)
Beta: 0.33
Market Capitalization: $10,279.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.45 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $2.10 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: 0.00
Estmated Long-Term EPS Growth Rate: 13.30% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 21.52
Trailing 12 Months: 16.23
PEG Ratio: 1.62
Price Ratios
Price/Book: 3.17
Price/Cash Flow: 11.98
Price / Sales: 4.44
EPS Growth
vs. Year Ago Period: 21.21%
vs. Previous Quarter: 8.11%
Sales Growth
vs. Year Ago Period: 10.79%
vs. Previous Quarter: 7.90%
ROE
03/31/22 - 20.92
12/31/21 - 20.58
09/30/21 - 20.71
ROA
03/31/22 - 10.62
12/31/21 - 10.30
09/30/21 - 10.22
Current Ratio
03/31/22 - 2.19
12/31/21 - 1.39
09/30/21 - 1.90
Quick Ratio
03/31/22 - 1.85
12/31/21 - 1.17
09/30/21 - 1.58
Operating Margin
03/31/22 - 27.88
12/31/21 - 27.27
09/30/21 - 26.90
Net Margin
03/31/22 - 23.29
12/31/21 - 22.76
09/30/21 - 26.61
Pre-Tax Margin
03/31/22 - 28.63
12/31/21 - 27.79
09/30/21 - 32.00
Book Value
03/31/22 - 14.27
12/31/21 - 13.58
09/30/21 - 13.22
Inventory Turnover
03/31/22 - 2.47
12/31/21 - 2.43
09/30/21 - 2.46
Debt-to-Equity
03/31/22 - 0.46
12/31/21 - 0.35
09/30/21 - 0.52
Debt-to-Capital
03/31/22 - 31.28
12/31/21 - 26.11
09/30/21 - 34.23
 

Powered by Zacks Investment Research ©